Whitehawk Therapeutics, Inc. (Nasdaq: WHWK) announced its financial results for the quarter ended September 30, 2026, and provided updates on its clinical development pipeline. The company reported cash, cash equivalents, and short-term investments totaling $169.7 million as of September 30, 2026, an increase from $145.7 million at the end of 2025. The company stated that this cash balance is anticipated to fund operations into the second half of 2028.
For the three months ended September 30, 2026, Whitehawk reported research and development expenses of $18.1 million, compared to $14.3 million for the same period in 2025. The company recorded a net loss of $21.2 million for the quarter, or $0.23 per share, compared to a net loss of $17.7 million, or $0.26 per share, in the prior year.
On the operational front, Whitehawk initiated a Phase 1 clinical trial for its antibody drug conjugate (ADC) candidate HWK-206 in the United States. The company noted that this marks the third of its original ADC programs to enter clinical development within the last 12 months. HWK-206 received Fast Track designation from the U.S. Food and Drug Administration (FDA). The trial is designed to evaluate an accelerated sequence of planned dose levels, starting at 3 mg/kg, with an initial focus on patients with small-cell lung cancer. Initial Phase 1 data for HWK-206 is expected by year-end 2027.
The company also reported that it submitted an Investigational New Drug (IND) application in China and anticipates activating its first clinical sites in the country in the first quarter of 2027. Additionally, Whitehawk provided updates on its other programs, stating it remains on track to report initial Phase 1 data from HWK-007 and HWK-016 in the first half of 2027. The company presented real-world analyses supporting the durability of the PTK7 and MUC16 targets at the World Conference on Lung Cancer 2026 and the International Gynecologic Cancer Society 2026, respectively.
